Screening for Anal Cancer and Precancer in Women With HIV (SANCA)
ConditionAnal Canal Cancer
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age45+
SponsorKarolinska Institutet
About this trial
The main aim of the SANCA study is to evaluate the feasibility, cost-effectiveness, and acceptability of implementing international anal cancer screening guidelines for women living with HIV in Sweden, integrating health economic and patient-centered approaches.
Secondly the investigators wish to investigate the predictive potential of DNA methylation markers for the clinical progression of precancerous anal lesions in women with HIV, combining prospective molecular biology analysis with clinical data from registries.
Eligibility criteria
Qualifiers
Women (biological sex) with HIV
45 years old or older
attending the out-patient HIV departments at Karolinska University Hospital in Stockholm, the South Hospital in Stockholm, and Sahlgrenska University Hospital in Gothenburg
Disqualifiers
Women who have had anal cancer
women who have had rectal amputation
Trial design
Treatments tested in this trial
- anal HPV screening
Treatment groups
1,000 Participants
are divided into 1 treatment groupSponsors and collaborators
Karolinska Institutet
Lead sponsor
Karolinska University Hospital
Collaborator
Stockholm South General Hospital
Collaborator
Sahlgrenska University Hospital
Collaborator
The Swedish Research Council
Collaborator
Source ClinicalTrials.gov